Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 3Recruiting 1Available 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1CNS 1

Conditions

Pheochromocytoma 1Neuroblastoma 1

Interventions

Specimen Handling 308Magnetic Resonance Spectroscopy 265pembrolizumab 254Carboplatin 185Cyclophosphamide 180Biopsy 168Cisplatin 157Gemcitabine 136Paclitaxel 131Bevacizumab 125fludarabine 118Nivolumab 111Radiotherapy 109Oxaliplatin 88Docetaxel 88Fluorouracil 85Capecitabine 84venetoclax 78Dexamethasone 77Pemetrexed 73Rituximab 70Leucovorin 69Drug Therapy 69durvalumab 67atezolizumab 67Radiosurgery 65Blood Specimen Collection 65Standard of Care 64Doxorubicin 64Radiation 60

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × 3-Iodobenzylguanidine × 90 days × Clear all
NCT00107289 2026-05-29

Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
200 enrolled
CNSEndocrine

Neuroblastoma, Pheochromocytoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡